University of Florence

Florence 50139

0 studies enrolling now · 9 studies all time

What they study most

Essential Thrombocythemia, Hepatocellular Carcinoma, High Risk Essential Thrombocythemia, High Risk Polycythemia Vera, Idiopathic Myelofibrosis, Liver Decompensation, Myelofibrosis, Myeloproliferative Disease, Non-Hodgkin Lymphoma, Polycythemia Vera, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis

Studies at this site

• A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) — Running, not enrolling
• To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) — Stopped early
• An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib — Status unconfirmed
• The Second Multicenter Hemophilia Cohort Study — Completed
• Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) — Completed
• Correlative Biomarker Study in Patients With Myeloproliferative Disorders — Completed
• Familial Myeloproliferative Disorders — Completed
• Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS) — Completed
• Assessment of SpondyloArthritis Society (ASAS) Classification and Diagnostic Criteria for Early Axial Spondyloarthritis (SpA) — Status unconfirmed